louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06858072: Transverse Friction Massage Versus Instrumented Assisted Soft Tissue Mobilization in Quadratus Lumborum Syndrome
Official title: Comparative Effects of Transverse Friction Massage Versus Instrument-assisted Soft Tissue Mobilization on Pain, Range of Motion, and Posture in Patients With Quadratus Lumborum Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Quadratus Lumborum Syndrome
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-03-05
Enrollment: 34
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To find effective therapeutic interventions for QLS, a study is being conducted to compare the efficacy of two promising techniques: Transverse Friction Massage (TFM) and Instrument-Assisted Soft Tissue Mobilization (IASTM) . Participants will be randomly assigned to either the TFM or IASTM groups. Outcome measures will be collected before and after the intervention, including pain levels assessed through NPRS, range of motion using inclinometer and posture by measuring leg length discrepancy with tape method.Non probability convenience sampling will be used and 34 partcipants will be randomly allocated in two groups after meeting inclusion criteria.Both groups will receive hotpack for 10-15min.Stretching quadratus lumborum will also be performed with strengthening on the opposite side of affected quadratus lumborum.This methodology provides a solid assessment of the effectiveness of TFM and IASTM for Quadratus Lumborum Syndrome therapy.


Eligibility criteria: Inclusion Criteria:

* Age group between 18-40years
* Males only with target population was office workers
* NPRS\>4
* Patients with a positional fault of the pelvis (lateral tilt)
* Patients having chronic LBP for more than six months
* Hyperirritable spot or taut band
* Positive jump sign for trigger points/ Referred pain related to the trigger point area
* Positive Lewis's functional palpation test for QL overactivity
* At least one trigger point in Quadratus lumborum
* Leg length discrepancy due to QL tightness

Exclusion Criteria:

* Congenital or acquired spinal deformities
* Spinal stenosis or radiculopathy
* Diagnosed disc prolapse
* Rheumatoid arthritis
* Any malignancy
* Recent history of surgery less than three months
* Acute infections

Primary outcomes:
measure: Numeric Pain rating scale(NPRS)
timeFrame: 8 weeks
measure: Range of motion
timeFrame: 8 weeks
measure: Posture
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Hafiz Medical and diagnostic Center johar town Lahore
state: Punjab
Study officials:
affiliation: Riphah international universiy
name: Faiza Amjad, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03156972: Speckle Tracking for Timing of Surgical Operation in Severe Mitral Regurge
Official title: Assessment of Rheumatic Heart Disease Patients With Chronic Severe Mitral Regurge by Speckle Tracking Echocardiography for Proper Timing of Surgical Operation.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatic Heart Disease
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-17
Enrollment: 30
Sex: ALL
Minimum age (years): 13
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Rhumatic heart disease patients with mitral regurge untile know had adibat for timming of surgical interferance our study aim to solve this problme using a new technic in echocardiography called speckle tracking which is more accurate in estimating a changes occure to myocyte of the heart and so chosing the proper time for surgery


Eligibility criteria: Inclusion Criteria:

* rhuematic heart disease with severe mitral regurge

Exclusion Criteria:

* non rheumatic mitral regurge

Primary outcomes:
measure: Timing of surgical operation in patients with chronic severe mitral regurge
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university
Study officials:
affiliation: Assiut University
name: Mohammed Aly, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05625672: EFFICIENCY OF HEMOVIGILANCE MODULE TRAININGS GIVEN TO NURSES
Official title: EVALUATION OF THE EFFICIENCY OF HEMOVIGILANCE MODULE TRAININGS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nurse's Role
Training Group, Sensitivity
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2022-11-23
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, parallel-group, placebo-controlled study
Primary purpose: OTHER

Brief summary: The aim of the present study is to determine the effectiveness of hemovigilance module training given to nurses.

Detailed description: 125 nurses from the clinic and intensive care units, who received the most intensive blood transfusion from two different hospitals, were included in the study as the intervention and control groups. The control group was not trained. Only the pretest was administered one week after the posttest. After the pre-test was applied to the nurses in the intervention group, five modules of training, which lasted four hours, were given using interactive methods. Five modules of training were prepared by the researcher. These five modules are the 1st module of training; definition of hemovigilance, its aims, the development of hemovigilance in the world and in Turkey, and legal legislation, Module 2; Donor selection, Blood donation Process, Phlebotomy and Donor reactions, Module 3; blood, blood transfusion, its purpose, properties of blood and blood components, Blood transfusion process, Module 4; acute and delayed transfusion reactions and management, Module 5; It consists of the national hemovigilance system, the organization of the hemovigilance system at the hospital level, Traceability, Trace-back from the Patient to the Donor, and Look-back from the Donor to the Patient. the training was over, the final test was administered. One month later, this test was repeated.

Eligibility criteria: Inclusion Criteria:

She/He voluntarily agrees to participate in the research, Working as a nurse in the clinic and intensive care unit where blood transfusions are the most, Working for at least 6 months,

Exclusion Criteria:

Nurses working in the emergency and operating rooms, in clinics where blood transfusion is not performed the most, Being a new nurse, On maternity leave and maternity leave, Having an external assignment, Nurses working in the polyclinic,

Primary outcomes:
measure: Hemovigilance Information Form
timeFrame: 5 hours or 1 month
measure: Information Form on Blood Transfusion Complications
timeFrame: 5 hours or 1 month
measure: Information Form on Blood Transfusion Applications
timeFrame: 5 hours or 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yıldırım Beyazıt University
Study officials:
References:
Clinical trial NCT01937572: Visionaire: A Prospective Study
Official title: Visionaire Versus Conventional Knee Arthroplasty: A Prospective Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Osteoarthritis
Keywords: Total knee arthroplasty (TKA)
Computer aided systems
Lead sponsor: The Hawkins Foundation
Sponsor class: OTHER
First posted: 2013-09-09
Enrollment: 149
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of the current study is to validate the technology of MRI-based alignment for total knee replacements and to collect data on potential advantages of the computer aided system.

1. It is hypothesized that there will be no significant differences in position, loosening, or function of the Visionaire total knee as compared to the conventional total knee.
2. It is hypothesized that the Visionaire total knee will be significantly better with regard to operative time, tourniquet time, blood loss, and procedural set-up, turnover time, and overall costs.


Eligibility criteria: Inclusion Criteria:

* Adult patients with sufficient symptoms from articular knee pathology to be an appropriate candidate for TKA

Exclusion Criteria:

* prior TKA
* ipsilateral upper tibial or distal femoral osteotomy
* ipsilateral total hip arthroplasty
* patient with significant \>15o varus or valgus
* morbid obesity or those patients unable to have an MRI based on thigh circumference (22 cm or less)

Primary outcomes:
measure: Knee Society Score
timeFrame: one year
Secondary outcomes:
measure: Degrees off normal AP and lateral alignment
timeFrame: one year
Other outcomes:
measure: Total blood loss
timeFrame: two days
measure: Operative time
timeFrame: one day
measure: Operative room setup and turnover times
timeFrame: one day
measure: Procedural cost
timeFrame: one day
Locations:
city: Greenville
country: United States
facility: Steadman Hawkins Clinic of the Carolinas - Greenville Hospital System
state: South Carolina
Study officials:
affiliation: Steadman Hawkins Clinic of the Carolinas - Greenville Hospital System
name: Brian Burnikel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04367272: Is Second Knee at Risk During Simultaneous Bilateral Total Knee Arthroplasty.
Official title: Is Second Knee at Risk During Simultaneous Bilateral Total Knee Arthroplasty.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis, Knee
Infection
Periprosthetic Fracture Around Prosthetic Joint Implant
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2020-04-29
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effects of single-team simultaneous bilateral total knee arthroplasty on peri- and postoperative complications are clear. The investigators hypothesized that second knee at risk during single-team simultaneous bilateral total knee arthroplasty and have more early postoperative complication rates than the first knee. Therefore, this prospective study compared minor and major local complications for 90 days postoperatively between the first and second during knee single-team simultaneous bilateral total knee arthroplasty.

Detailed description: The investigators would like to compare operation related technical complications and periprosthetic joint infection rate between the first and second knee.

Eligibility criteria: Inclusion Criteria:

* Primary bilateral knee osteoarthritis with refractory to conservative treatment
* Patients who accept participation in the research and the randomization

Exclusion Criteria:

* no history of malignancy
* less than 75 years old
* severe cardiac insufficiency and morbid obesity

Primary outcomes:
measure: Local complications
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04533672: Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making
Official title: Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bladder Cancer
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Swiss National Science Foundation
First posted: 2020-08-31
Enrollment: 182
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The therapeutic approach to bladder cancer is strongly dependent on tumor stage and grade. Patients with non-muscle-invasive tumors (NMIBC) are usually treated with surgical resection of the tumor alone, whereas patients with muscle-invasive tumors (MIBC) ideally undergo neoadjuvant chemotherapy (NCT) and subsequent cystectomy. Magnetic Resonance Imaging (MRI) is emerging as a new staging modality, given its non-invasiveness and excellent soft tissue contrast. However, more advanced multiparametric MRI techniques are yet to be comprehensively investigated in patients with bladder cancer. Recently, genetic characteristics of bladder tumors have been identified that show significant impact on response rates to neoadjuvant treatment. The combination of new multiparametric MRI (mpMRI) techniques and genetic analyses of the tumor might allow for a better assessment of the expected clinical course of the disease and support more personalized treatment approaches.


Eligibility criteria: Inclusion Criteria:

* Patients with confirmed or suspected primary bladder cancer and a circumscribed tumor/focal thickening of the bladder wall on initial imaging (ultrasound, CT) or cystoscopy with an approx. size of ≥ 1.5 cm/for which at least 2-3 TUR-B resection loops are necessary
* Informed consent as documented by signature (Informed Consent Form)

Exclusion Criteria:

* Prior TUR-B or other bladder treatment, prior treated bladder cancers, prior pelvic irradiation
* Women who are pregnant or breast-feeding. Female participants who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential.
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* Previous enrolment into the current study
* Patients with non-MRI compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-MRI compatible implants).

Primary outcomes:
measure: Muscle-invasiveness
timeFrame: through study completion, an average of 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich
state: ZH
Study officials:
References:
Clinical trial NCT00044772: Study Evaluating Venlafaxine ER in Patients With Panic Disorder
Official title: A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Panic Disorder
Keywords: Panic
Disorder
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2002-09-06
Enrollment: 653
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.


Eligibility criteria: Inclusion Criteria:

* Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1
* Have sufficient symptoms to require anxiolytic drug therapy
* Have a score ≥4 on the Clinical Global Impressions Scale (CGI) severity of illness item at screening and baseline

Exclusion Criteria:

* Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine
* History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension)
* Clinically important abnormality on screening physical examination, vital signs, electrocardiogram (ECG), laboratory tests or urine drug screen

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05649072: Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Official title: Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ovarian Cancer
Breast Cancer
Colorectal Cancer
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Community Outreach and Engagement Fund for Underserved Texans
First posted: 2022-12-13
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

Detailed description: Objectives:

1. To identify underserved women at risk for hereditary breast and colorectal cancers and would be eligible for standard of care genetic counseling and testing using national screening guidelines.
2. To provide education to providers and patients regarding hereditary cancers using previously IRB approved educational material and short video.

Eligibility criteria: Inclusion Criteria:

Any woman scheduled at Project VALET mammography screening mobile units will be eligible for this study.

Exclusion Criteria:

Primary outcomes:
measure: To identify underserved women at risk for hereditary breast and colorectal cancers eligible for standard-of-care genetic counseling using national screening guidelines.
timeFrame: through study completion; an average of 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Arun Banu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03335072: Kebele Elimination of Trachoma for Ocular Health
Official title: Kebele Elimination of Trachoma for Ocular Health
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Trachoma
Keywords: Azithromycin
Mass Drug Administration
Antibiotic Resistance
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: National Eye Institute (NEI)
name: Eyu-Ethiopia
name: Bahir Dar University
First posted: 2017-11-07
Enrollment: 320000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Detailed description: The investigators propose to randomize at the kebele level, which consist of approximately 15 villages, 4,000 residents, and are served by a single primary school. Eighty kebeles will be randomized to one of four arms: 1) annual mass azithromycin distribution per WHO guidelines (Annual); 2) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years (Core Group-Age); 3) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years with a positive chlamydial PCR test (Core Group-PCR); or 4) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years positive for conjunctival inflammation as assessed from annual photography (Core Group-TI). The primary outcome for the trial will be the ocular chlamydia prevalence at 12, 24, and 36 months. Secondary outcomes will include bacterial load of ocular chlamydia via quantitative PCR, the prevalence of clinically active trachoma assessed at 12, 24, and 36 months, and serology via dried blood spot at baseline and 36 months.

Eligibility criteria: Inclusion Criteria:

* All individuals in all communities will be eligible for annual mass azithromycin distribution per WHO guidelines.

Exclusion Criteria:

* Those who do not consent.

Primary outcomes:
measure: Ocular chlamydia measured in a population based age-stratified sample of the entire community
timeFrame: 36 months
Secondary outcomes:
measure: Infectious load of chlamydia among 0-9 year-old children infected with ocular chlamydia
timeFrame: 36 months
measure: Conjunctival inflammation
timeFrame: 36 months
measure: Seropositivity to C. trachomatis antibodies CT694 and Pgp3
timeFrame: 36 months
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Proctor Foundation
state: California
city: Bahir Dar
country: Ethiopia
facility: Eyu-Ethiopia
Study officials:
affiliation: University of California, San Francisco
name: Tom M Lietman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Hadley Burroughs, MSPH
role: STUDY_DIRECTOR
References:
Clinical trial NCT02865772: Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns
Official title: Reference Ranges of Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infant, Newborn, Diseases
Lead sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor class: OTHER
First posted: 2016-08-12
Enrollment: 248
Sex: ALL
Minimum age (years): 10
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: healthy newborns

Brief summary: The aim of this study to determine the reference ranges of LBC on gastric aspirate in healthy term newborns.

Detailed description: Lamellar bodies represent the storage form of lung surfactant. Surfactant is produced in alveolar type II cells and transported to the alveolar surface as lamellar bodies. Lamellar bodies are present in the amniotic fluid and also gastric aspirate.It has become a preferred test for determine fetal lung maturity, because of the rapid, inexpensive, easily accessible and easily applicable method.

Eligibility criteria: Inclusion Criteria:

* infants born at ≥ 37 weeks of gestation and birth weight ≥ 2500 g

Exclusion Criteria:

* intubated immediately after birth, infants with respiratory distress, infants with gestational pathology that can influence fetal lung maturity (cases with premature rupture of membranes, preeclampsia/eclampsia, gestational diabetes, oligohydramnios/polyhidramnios or antenatal steroid use), infants with major congenital or chromosomal abnormalities and lack of parental consent, therapeutic infusion was given in the amniotic cavity or if gastric aspirate contaminated by meconium, pus or blood.

Primary outcomes:
measure: normal levels of lamellar body counts on gastric aspirate in healthy term newborns.
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: